About Us
About Us
Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. We are utilizing over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.
Our lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and we recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.
As a global leader in understanding intestinal barrier biology, we leverage patented technology to detect and measure the activity of digestive enzymes escaping the gut which has been linked to numerous human diseases.
We believe that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.
We have a passionate team focused on delivering therapies to patients.

We Are Palisade Bio

Leadership Team
Our leadership is comprised of a team of experts in clinical development, commercialization, and pipeline development who are passionate about the advancement of science and medicine.
Thomas Hallam, Ph.D.
Chief Executive Officer
JD Finley
Chief Financial Officer
Michael Dawson, M.D.
Chief Medical Officer
John Rodenrys
Co-Founder, EVP, Chief Technology Officer
Robert McRae
Senior Vice President, Operations and Strategic Development
Board Of Directors
James R. Neal
Chairman of the Board
Thomas Hallam, Ph.D.
Chief Executive Officer
Stephanie C. Diaz
Director
Donald A. Williams
Director
Mary Ann Gray, Ph.D.
Director
Cristina Csimma, Pharm.D., MHP
Director
Robert J. Trenschel, D.O.
Director
Binxian Wei
Director
Clinical Steering Committee
David Berry, M.D.
Clinical Steering Committee Chair
Mark Talamini, M.D.
Clinical Steering Committee Member
Jerrold Levy, M.D.
Clinical Steering Committee Member
Steven D. Wexner, M.D.
Clinical Steering Committee Member
Ronald Hurst, M.D., F.A.C.S.
Clinical Steering Committee Member
Paul A. Checchia, M.D.
Clinical Steering Committee Member
Scientific Advisory Board
Geert Schmid-Schönbein, Ph.D.
Scientific Co-Founder of Leading BioSciences, Scientific Advisory Board Member
David B. Hoyt, M.D., F.A.C.S.
Scientific Co-Founder of Leading BioSciences, Scientific Advisory Board Member
Darin Saltzman, M.D., Ph.D.
Scientific Advisory Board Member
Tim Tully, Ph.D.
Scientific Advisory Board Member
Careers
Named One of San Diego’s Cool Companies by the San Diego Venture Group
The Palisade Bio team is dedicated to developing new therapies for a range of serious, widespread health conditions that impact millions of patients every year. We are driven by science—and supported by a culture of innovation, openness and problem-solving.
Join us in our mission.